Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31556092 | 0.86 | ALDH1A1 (0.57) | KMT2AALDH1A1MEN1KDM4ESMN1; SMN2 | |
| SCHEMBL15540355 | 0.84 | HPGD (0.53) | ALDH1A1KDM4ESMN1; SMN2PARP10PARP14 | |
| SCHEMBL30015569 | 0.77 | DGAT1 (0.49) | KMT2APARP10PARP15HPGD | |
| SCHEMBL24699358 | 0.77 | DGAT1 (0.49) | KMT2APARP10PARP15HPGD | |
| SCHEMBL3728595 | 0.77 | GAA (0.53) | KMT2AALDH1A1MEN1KDM4ESMN1; SMN2 | |
| SCHEMBL3091338 | 0.77 | PARP15 (0.48) | KMT2AALDH1A1MEN1KDM4ESMN1; SMN2 | |
| SCHEMBL423775 | 0.76 | PARP15 (0.58) | ALDH1A1KDM4ESMN1; SMN2PARP10PARP15 | |
| SCHEMBL28348830 | 0.76 | HPGD (0.50) | KMT2AALDH1A1MEN1KDM4ESMN1; SMN2 | |
| SCHEMBL31556089 | 0.75 | ALDH1A1 (0.53) | KMT2AALDH1A1MEN1KDM4ESMN1; SMN2 | |
| SCHEMBL28706432 | 0.74 | KMT2A (0.47) | KMT2AALDH1A1MEN1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251333-A1 | Biphenyl derivatives as P-38 kinase inhibitors | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| EP-1990338-B1 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7700622-B2 | p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| EP-1990338-A2 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1687284-B1 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1687284-A2 | p-38 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005012241-A2 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-10 | — | — | WO | disclosed |
| US-20050020590-A1 | P-38 kinase inhibitors | NOVARTIS AG (CH) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111999-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | KMT2A 3583/4885ALDH1A1 3548/4885MEN1 4480/4885 |
| US-20050020590-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | KMT2A 3537/4885ALDH1A1 3694/4885MEN1 4241/4885 |
| US-20100234404-A1 | P-38 Kinase Inhibitors | MAPK8, MAP3K8, MAPK1 | KMT2A 3583/4885ALDH1A1 3548/4885MEN1 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.